MedTrace Logo

A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT01045577 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2018-12-10

No results posted yet for this study

Summary

A double-blind, placebo-controlled, randomized, parallel-group study to evaluate the activity of oral AB1010 in adults patients with moderate to severe chronic plaque psoriasis

Conditions

Interventions

DRUG

Masitinib

6 mg/kg/day

DRUG

Masitinib

3 mg/kg/day

DRUG

Placebo

Placebo matching masitinib (3 mg/kg/day and 6 mg/kg/day)

Sponsors & Collaborators

  • AB Science

    lead INDUSTRY

Principal Investigators

  • Jean-Paul ORTONNE, MD · CHU NICE

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2006-01-31
Completion
2008-02-29

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01045577 on ClinicalTrials.gov